Synonyms: compound 8g [PMID: 22959556] | MP-513 | MP513 | Teneli
teneligliptin is an approved drug (Japan (2012), S Korea (2014))
Compound class:
Synthetic organic
Comment: Teneligliptin is a long-acting, orally bioavailable dipeptidyl peptidase 4 (DPP-4) inhibitor [3]. It was developed for clinical potential in type 2 diabetes management, to improve glycemic control. In addition to their anti-diabetic activity, DPP4 inhibitors may have renal and cardiovascular protective effects.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Immunopharmacology Comments |
Teneligliptin has been shown to reduce the pro-inflammatory phenotype of perivascular adipose tissue, an effect that inhibits atherogenesis and which may partly underlie its noted cardioprotective effects [2]. Teneligliptin's effects on perivascular adipose tissue are likely related to its action of increasing GLP-1 levels, since a GLP-1 analog suppressed pro-inflammatory activation of macrophages and adipocytes. |